These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 25407896

  • 1. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [Abstract] [Full Text] [Related]

  • 2. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [Abstract] [Full Text] [Related]

  • 3. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
    Gertz MA.
    Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
    [Abstract] [Full Text] [Related]

  • 4. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
    [Abstract] [Full Text] [Related]

  • 5. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [Abstract] [Full Text] [Related]

  • 6. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2020 Jul; 95(7):848-860. PubMed ID: 32267020
    [Abstract] [Full Text] [Related]

  • 7. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2022 Jun 01; 97(6):818-829. PubMed ID: 35429180
    [Abstract] [Full Text] [Related]

  • 8. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
    Charliński G, Jurczyszyn A, Wiktor-Jedrzejczak W.
    Przegl Lek; 2014 Jun 01; 71(2):102-9. PubMed ID: 25016786
    [Abstract] [Full Text] [Related]

  • 9. [Amyloid light chain amyloidosis].
    Suzuki K, Shimizu T.
    Brain Nerve; 2014 Jul 01; 66(7):795-809. PubMed ID: 24998824
    [Abstract] [Full Text] [Related]

  • 10. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G.
    Presse Med; 2012 Mar 01; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [Abstract] [Full Text] [Related]

  • 11. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G, Wiater E, Jedrzejczak WW.
    Pol Merkur Lekarski; 2012 Apr 01; 32(190):217-20. PubMed ID: 22708276
    [Abstract] [Full Text] [Related]

  • 12. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schönland SO, Schnabel PA, Schuster T, Röcken C, Giannitsis E, Katus HA, Frey N.
    Amyloid; 2014 Sep 01; 21(3):202-10. PubMed ID: 25007036
    [Abstract] [Full Text] [Related]

  • 13. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G.
    J Clin Oncol; 2012 Dec 20; 30(36):4541-9. PubMed ID: 23091105
    [Abstract] [Full Text] [Related]

  • 14. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
    Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA.
    Am J Hematol; 2010 Oct 20; 85(10):757-9. PubMed ID: 20872958
    [Abstract] [Full Text] [Related]

  • 15. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S, Venner CP, Sachchithanantham S, Lane T, Rannigan L, Foard D, Pinney JH, Gibbs SD, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.
    Br J Haematol; 2014 Sep 20; 166(6):842-8. PubMed ID: 24930361
    [Abstract] [Full Text] [Related]

  • 16. Systemic immunoglobulin light-chain amyloidosis.
    Comenzo RL.
    Clin Lymphoma Myeloma; 2006 Nov 20; 7(3):182-5. PubMed ID: 17229332
    [Abstract] [Full Text] [Related]

  • 17. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.
    Amyloid; 2016 Dec 20; 23(4):254-259. PubMed ID: 27879147
    [Abstract] [Full Text] [Related]

  • 18. Light chain amyloidosis 2012: a new era.
    Gatt ME, Palladini G.
    Br J Haematol; 2013 Mar 20; 160(5):582-98. PubMed ID: 23294331
    [Abstract] [Full Text] [Related]

  • 19. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G.
    Ann Hematol; 2012 Jan 20; 91(1):89-92. PubMed ID: 21533608
    [Abstract] [Full Text] [Related]

  • 20. Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis.
    Sugiyama A, Asahina M, Takeda Y, Shiojiri T, Sano K, Ikeda S, Kuwabara S.
    Amyloid; 2014 Sep 20; 21(3):218-20. PubMed ID: 24970351
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.